[1]鄢学,李承治,张帆,等.肾动脉消融治疗顽固性高血压的相关影响因素[J].心血管病学进展,2016,(3):311-314.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.026]
　YAN Xue,LI Chengzhi,ZHANG Fan,et al.The Related Factors of Renal Denervation for Resistant Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):311-314.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.026]
点击复制

肾动脉消融治疗顽固性高血压的相关影响因素()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年3期
页码:
311-314
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
The Related Factors of Renal Denervation for Resistant Hypertension
作者:
鄢学1; 李承治2; 张帆1; 曾珠1; 陈苗苗1; 徐蜀英1; 综述; 向阳1; 审校
1.重庆市万州区人民医院,重庆 404100; 2.四川省双流县第一人民医院,四川 成都 610200
Author(s):
YAN Xue1; LI Chengzhi2; ZHANG Fan1; ZENG Zhu1; CHEN Miaomiao1; XU Shuying1; XIANG Yang1
1.Wanzhou People's Hospital of Chongqing,Chongqing 404100,China; 2.The First People's Hospital ofShuangliu County,Chengdu 610200,Sichuan,China
关键词:
顽固性高血压;  肾动脉消融;  影响因素
Keywords:
Resistant hypertension;  Renal denervation;  Influence factors
分类号:
R544.1
DOI:
10.16806/j.cnki.issn.1004-3934.2016.03.026
文献标志码:
A
摘要:
肾动脉消融治疗顽固性高血压这种新技术,国内外学者对此进行了一系列研究,然而所得出的结果相差甚异。各试验在纳入人群、研究设计、手术操作流程等方面存在一定差异,现通过对各临床试验相关影响因素进行分析来说明目前存在的一些问题。
Abstract:
Renal denervation is a new technology in the treatment of resistant hypertension. International and Chinese scholars conducted a series of research studies, with varying results. Some of the differences includes enrollment of people in the clinical trials, research design, operational process and much more. This article analyzes the relevant influence factors of the clinical tests to explain existing problems.

参考文献/References:

[1] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension[J]. Blood Press, 2014, 23(1):3-16.
[2] Fagard RH. Resistant hypertension[J]. Heart,2012,98(3):254-261.
[3] de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8 295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring[J].Hypertension,2011, 57(5):898-902.
[4] Tsioufis C,Kordalis A,Flessas D,et al.Pathophysiology of resistant hypertension:the role of sympathetic nervous system[J]. Int J Hypertens,2011,2011:642416.
[5] Esler MD, Bohm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension:36 month results from the SYMPLICITY HTN-2 randomized clinical trial[J]. Eur Heart J,2014,35(26):1752-1759.
[6] Bhatt DL, Kandzari DE, O'Neill WW, et al.A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[7] Esler MD,Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension:one-year results from the Symplicity HTN-2 randomized, controlled trial[J]. Circulation,2012,126(25):2976-2982.
[8] Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J].Lancet,2009,373(9671): 1275-1281.
[9] Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[10] Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension[J]. Hypertension, 2014,63(5):991-999.
[11] Bohm M, Mahfoud F, Ukena C, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension[J]. Hypertension, 2015,65(4):766-774.
[12] Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial[J]. Eur Heart J,2015,36(4):219-227.
[13] Savard S, Frank M, Bobrie G, et al. Eligibility for renal denervation in patients with resistant hypertension:when enthusiasm meets reality in real-life patients[J].J Am Coll Cardiol,2012, 60(23):2422-2424.
[14] Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan—First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients[J]. Circ J,2015,79(6):1222-1229.
[15] Persu A, Azizi M, Burnier M, et al. Residual effect of renal denervation in patients with truly resistant hypertension[J]. Hypertension,2013,62(3):450-452.
[16] Esler M.Illusions of truths in the Symplicity HTN-3 trial:generic design strengths but neuroscience failings[J]. J Am Soc Hypertens,2014,8(8):593-598.
[17] Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure:a systematic review of randomized controlled trials[J]. J Hypertens,2006,24(2):215-233.
[18] Conlin PR, Chow D, Miller ER 3rd, et al. The effect of dietary patterns on blood pressure control in hypertensive patients:results from the Dietary Approaches to Stop Hypertension(DASH)trial[J]. Am J Hypertens,2000,13(9):949-955.
[19] Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension(DENERHTN):a multicentre, open-label, randomised controlled trial[J]. Lancet, 2015,385(9981):1957-1965.
[20] Jung O, Gechter JL, Wunder C, et al.Resistant hypertension? Assessment of adherence by toxicological urine analysis[J]. J Hypertens,2013,31(4):766-774.
[21] Calhoun DA, Jones D, Textor S, et al. Resistant hypertension:diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J]. Hypertension,2008,51:1403-1419.
[22] Yiannakopoulou E, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control[J]. Eur J Cardiovasc Prev Rehabil,2005,12(3):243-249.
[23] Holt E, Joyce C, Dornelles A, et al. Sex differences in barriers to antihypertensive medication adherence:findings from the cohort study of medication adherence among older adults[J]. J Am Geriatr Soc,2013,61(4):558-564.
[24] Rosa J, Widimsky P, Tousek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension:six-month results from the Prague-15 study[J]. Hypertension,2015,65(2):407-413.
[25] Krieger EM, Drager LF, Giorgi DM, et al. Resistant hypertension optimal treatment trial:a randomized controlled trial[J].Clin Cardiol,2014,37(1):1-6.
[26] Williams B. Spironolactone “A Clear Winner” for Resistant Hypertension[C]. London:European Society of Cardiology Congress, 2015.
[27] Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for the treatment of resistant essential hypertension:the first Dutch experience[J]. Neth Heart J,2011,19(7-8):319-323.
[28] Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension[J]. Hypertension,2015,65(6):1202-1208.
[29] Luscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3:confused at the higher level?[J]. Eur Heart J,2014,35(26):1706-1711.

相似文献/References:

[1]王恺皞,综述,蒋雄京,等.顽固性高血压的器械治疗[J].心血管病学进展,2016,(2):112.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.004]
　WANG Kaihao,JIANG Xiongjing.Device-based Therapies for Resistant Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):112.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.004]
[2]肖蓉雪 刘宗军.肾动脉去交感神经术治疗顽固性高血压的研究进展[J].心血管病学进展,2019,(8):1138.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
　XIAO Rongxue,LIU Zongjun.Treatment of Resistant Hypertension by Renal Denervation[J].Advances in Cardiovascular Diseases,2019,(3):1138.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]

备注/Memo

备注/Memo:
作者简介:鄢学(1988—),住院医师,硕士,主要从事高血压、心力衰竭研究。Email:cqmuyanxue2012@163.com
更新日期/Last Update: 2016-05-25